Skip to content

Biomarkers of Pediatric Heart Failure

Study of Some Biomarkers Of Heart Failure In Children Attending Pediatric Cardiology Department Of Assiut University Children Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05969925
Enrollment
70
Registered
2023-08-01
Start date
2023-09-01
Completion date
2024-09-02
Last updated
2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Heart failure (HF) is a clinical syndrome where the heart is unable to pump the blood required to meet the metabolic demands of the body. Heart failure in children can result from a variety of structural or functional cardiac disorders with subsequent failure of the ventricles to fill with or eject blood

Detailed description

Cardiac biomarkers are useful as diagnostic and prognostic tools, especially in patients with atypical signs and symptoms. High rate of complication in HF led to the search for suitable cardiac biomarker that diagnose heart failure as early as possible, predict outcome, reflect response to treatment and help in staging of heart failure and determine risk (6) . In pediatrics, biomarkers of heart failure are particularly important for the early identification and risk stratification of patients with systemic diseases and associated risk for early development of heart failure. Good biomarkers have the following characteristics: high sensitivity and specificity, the possibility of simultaneous processing of many samples, short analysis time, low cost, and good clinical applications, thus predicting the risk of heart failure and the associated prognosis as well as the adequacy of monitoring \[7\]. . Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein covalently bound to matrix metalloproteinase-9 which was first isolated from neutrophils. It belongs to the lipocalin family, NGAL has been found to be elevated in both plasma and urine in patients with HF.(8) NGAL also acts as a growth and differentiation factor in the renal epithelium \[9\].

Interventions

DIAGNOSTIC_TESTnew biomarkers for heart failure

assess efficacy of new biomarkers for heart failure

Sponsors

Assiut University
CollaboratorOTHER
Ahmed Ali Mahny
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 16 Years

Inclusion criteria

Children from 1 month to 16 years old admitted to Assiut children University Hospital the Pediatric Cardiology unit with clinical manifestation of heart failure according to Ross classification either due to congenital or due to acquired heart disease will be enrolled in the study

Exclusion criteria

Children with renal disease or failure, hepatic disease, pulmonary diseases will also excluded.

Design outcomes

Primary

MeasureTime frameDescription
serum level of Neutrophil gelatinase-associated lipocalin in pediatric heart failureone yearaccuarcy of serum level of Neutrophil gelatinase-associated lipocalin in heart failure

Contacts

Primary ContactAhmed A Mohammed, Dr.
ahmedna1712@gmail.com+18677791

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026